Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist, and Executive Director of Employer Services at the City of Hope Comprehensive Cancer Center in Duarte, CA.

Iressa vs. Standard Chemo in Asian Never- or Light Ex-Smokers: Results of the IPASS Trial
Tue, 09/16/2008 - 09:08
Please Note: While this is Still Excellent Background Info, New Treatments and Procedures Have Emerged Since this Original Post
Author
Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

The European Society for Medical Oncology (ESMO) Congress, similar to ASCO but based in Europe, has been going on in Stockholm, where the results of a study called the First Line Iressa versus Carboplatin/Paclitaxel in Asia Study (taking some liberties to force it into the acronym "IPASS") was presented in the Presidential Symposium by my friend and Hong Kong-based colleague Tony Mok. This study, as shown in the schema below, randomized 1217 Asian patients with advanced NSCLC who had not received prior systemic therapy to either the oral EGFR inhibitor iressa (gefitinib) or the standard chemotherapy carboplatin/taxol (paclitaxel): IPASS summary 2 (click to enlarge)

It was conducted in 7 countries throughout Asia, and by including only Asian never-smokers or light former smokers (less than 10 "pack-years", the product of number of years smoked x packs per day; and must not have smoked in last two years), it was able to use clinical factors to heavily enrich for patients with EGFR mutations, who are known to have a high probability of responding to oral EGFR "tyrosine kinase inhibitors" (TKIs) like iressa and tarceva(erlotinib). In fact, Dr. Mok noted that there was a great practical advantage in being able to use clinical variables rather than molecular markers that required tissue: only 683/1217 (56%) of patients provided tissue for detecting the mutation, of whom mutation work could be completed in only 437 (36%). This highlights an important challenge in trying to use tissue markers to guide treatment decisions. Progression-free survival (PFS) was the primary endpoint, and it showed a significant difference favoring iressa overall. Among patients receiving iressa, 25% showed no progression after one year on treatment, compared with only 7% on chemotherapy alone. The overall "hazard ratio" (HR), a measure of improvement in progression-free survival over the entire course of treatment, was 0.74, corresponding to a 26% improvement on iressa vs. standard chemo. However, the results were very different for EGFR mutation-positive vs. EGFR mutation-negative patients. The patients with the mutation showed a more than doubling in progression-free survival with iressa (HR 0.48), while those without mutations did nearly three-times better in terms of PFS with chemo (HR 2.85). It wasn't surprising to see a response rate (RR) of 71.1% among EGFR-mutation positive patients who received iressa, or that it was remarkably higher than the RR of 1.1% seen in EGFR mutation-negative patients. What was interesting and somewhat surprising to see was that the patients with EGFR mutations also had a significantly higher RR on standard chemotherapy (47.3% vs. 23.5%). I'm actually not blown away by this, since we had already seen that patients with EGFR mutations on the TRIBUTE trial of carbo/taxol with either tarceva or placebo not only had a remarkably long survival on the tarceva arm, but they also had a significantly longer survival if assigned to chemo and placebo: tribute-mutation-status-eberhardt The important point in the figure above is that the two hatched lines travel together: patients with EGFR mutations showed the same superior survival, whether they received the EGFR inhibitor or not. In the IPASS study, the median overall survivals of the two arms are very similar: 18.6 months with iressa, and 17.3 months with chemo. This isn't a statistically significant difference, although more definitive survival results won't be available for another year or two. Finally, the investigators also included a qualify of life analysis that was more favorable in the recipients of iressa than those on chemo (p = 0.0148). What can we take from this? First, it's clear that in a selected population, EGFR inhibitors can perform as well or better than chemotherapy. In terms of which EGFR inhibitor, iressa is still widely used and potentially relevant in Asia, but outside of Asia tarceva has appeared to be more active in a broader population. I would find it nearly unfathomable that tarceva wouldn't look as good or better and would therefore extrapolate these results to the family of EGFR inhibitors. I'm not confident that iressa would perform as well in a broader population. I have already written that I do feel comfortable offering an EGFR inhibitor as a first line alternative to chemo in patients who have never-smoked and/or have a known EGFR mutation (see prior post). The results of this trial certainly corroborate my prior interpretation that this was acceptable. Is it optimal? Perhaps, but overall survival appears to be comparable between the two arms, and it may well be that there's no real practical difference between starting with chemo and then following with an EGFR inhibitor vs. starting with the EGFR inhibitor first line (I'd expect it to really be six of one, a half dozen of the other). If quality of life is better with the EGFR inhibitor, it's really just a question of whether they get it as first or second line treatment. Importantly, I wouldn't extrapolate these results to be applicable outside of a narrowly selected patient population. EGFR mutation is probably the purest version, and never- or minimal-smoking status along with being Asian help get you there. I would not expect these results to apply to a broader population, as illustrated by the response rate difference of 71% vs. 1% for Asian patients with vs. without EGFR mutations. Run this trial in North America and the results could be very different. Finally, it's quite interesting to see that patients with EGFR mutations not only had a superior survival even with chemo alone (as noted in the TRIBUTE trial, figure above), but now also show a much higher response rate with standard chemo. Unlike survival, which could be affected by patients just getting an EGFR inhibitor after chemo, the response rate to chemo is not affected by EGFR inhibitor therapy, so it shows that patients with activating EGFR mutations really have a different, more responsive form of lung cancer. We'll discuss this further in my next post, about a trial focusing exclusively on patients with EGFR mutations.

Next Previous link

Previous PostNext Post

Related Content

Image
Mandarin LCVL
Video
王林医生用普通话讨论重要的肺癌信息。这些信息包括靶向治疗、晚期疾病的症状、循环肿瘤 DNA、治疗方案等。我们鼓励您与社区中说普通话的人分享。 Dr. Lin Wang discusses important lung cancer information in Mandarin. This information includes targeted therapy, symptoms of advanced disease, circulating tumor DNA, treatment options, and more. We encourage you to share this with the Mandarin speakers in your community. To watch the complete Playlist visit: https://www.youtube.com/playlist?list=PLWsyUmdjLXhGnSxobmz4CBP3pxAj7nDa…;  
Image
Tell your story!  Apply now for the Clinical Trials Experiences through Storytelling Program
Article
We are excited to launch our third year of this program; tell your story and help us help others! Apply Online Now!     GRACE Patient Perspectives: Clinical Trials Experiences Storytelling Program Overview  
Image
Blood Cancer OncTalk
Video
Blood Cancer OncTalk was a live presentation that brought together top oncologists to discuss emerging concepts and treatment options in blood cancer. The program was chaired by Dr. Aaron Goodman, with the participation of Dr. Mazie Tsang, Hematologist / Oncologist; Dr. Autumn Jeong, Hematologist / Oncologist; Dr. Shaji Kumar, Hematologist / Oncologist; and Dr. Sridevi Rajeeve, Hematologist / Oncologist.

Forum Discussions

Hi Caregiver and welcome to Grace.  I'm sorry that you need to be here and hope we can help.  Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...

Hi Bob, Welcome to Grace.  I'm sorry about your sil.  Unfortunately, cancer becomes resistant to TKIs like tagrisso.  Sometimes all of the cancer becomes resistant at once and sometimes just parts...

Recent Comments

JOIN THE CONVERSATION
Hi Tammy,  Welome to Grace. …
By JanineT GRACE … on Tue, 05/16/2023 - 13:44
Concerned
By Tndiuka10 on Fri, 05/12/2023 - 21:13
Hi Caregiver and welcome to…
By JanineT GRACE … on Fri, 05/12/2023 - 14:20
Hi Bob, Welcome to Grace.  I…
By JanineT GRACE … on Tue, 05/02/2023 - 12:29